Activation of 5'-AMP-activated Kinase with Diabetes Drug Metformin Induces Casein Kinase 1&3x20AC; (CKI&3x20AC;)-dependent Degradation of Clock Protein mPer2.

Metformin is one of the most commonly used first line drugs for type II diabetes. Metformin lowers serum glucose levels by activating 5'-AMP-activated kinase (AMPK), which maintains energy homeostasis by directly sensing the AMP/ATP ratio. AMPK plays a central role in food intake and energy metabolism through its activities in central nervous system and peripheral tissues. Since food intake and energy metabolism is synchronized to the light-dark (LD) cycle of the environment, we investigated the possibility that AMPK may affect circadian rhythm. We discovered that the circadian period of Rat-1 fibroblasts treated with metformin was shortened by 1 h. One of the regulators of the period length is casein kinase lϵ (CKIϵ), which by phosphorylating and inducing the degradation of the circadian clock component, mPer2, shortens the period length. AMPK phosphorylates Ser-389 of CKIϵ, resulting in increased CKIϵ activity and degradation of mPer2. In peripheral tissues, injection of metformin leads to mPer2 degradation and a phase advance in the circadian expression pattern of clock genes in wild-type mice but not in AMPK α2 knock-out mice. We conclude that metformin and AMPK have a previously unrecognized role in regulating the circadian rhythm. [ABSTRACT FROM AUTHOR]